CD59 and Miyoshi myopathy: Here, we employed two small recombinant proteins, Ad35K++ and rILYd4, to eliminate or block CD46 and CD59, respectively, with the goal of increasing the efficacy of CDC triggered by daratumumab and isatuximab in MM cells.